Literature DB >> 34089062

Targeted HAI-2 deletion causes excessive proteolysis with prolonged active prostasin and depletion of HAI-1 monomer in intestinal but not epidermal epithelial cells.

Robert B Barndt1, Mon-Juan Lee1,2,3, Nanxi Huang1, Dajun D Lu1, See-Chi Lee1, Po-Wen Du1,4, Chun-Chia Chang5, Ping-Feng B Tsai5, Yu-Siou K Huang5, Hao-Ming Chang6, Jehng-Kang Wang4, Chih-Hsin Lai7, Michael D Johnson1, Chen-Yong Lin1.   

Abstract

Mutations of SPINT2, the gene encoding the integral membrane, Kunitz-type serine inhibitor HAI-2, primarily affect the intestine, while sparing many other HAI-2-expressing tissues, causing sodium loss in patients with syndromic congenital sodium diarrhea. The membrane-bound serine protease prostasin was previously identified as a HAI-2 target protease in intestinal tissues but not in the skin. In both tissues, the highly related inhibitor HAI-1 is, however, the default inhibitor for prostasin and the type 2 transmembrane serine protease matriptase. This cell-type selective functional linkage may contribute to the organ-selective damage associated with SPINT 2 mutations. To this end, the impact of HAI-2 deletion on matriptase and prostasin proteolysis was, here, compared using Caco-2 human colorectal adenocarcinoma cells and HaCaT human keratinocytes. Greatly enhanced prostasin proteolytic activity with a prolonged half-life and significant depletion of HAI-1 monomer were observed with HAI-2 loss in Caco-2 cells but not HaCaT cells. The constitutive, high level prostasin zymogen activation observed in Caco-2 cells, but not in HaCaT cells, also contributes to the excessive prostasin proteolytic activity caused by HAI-2 loss. HAI-2 deletion also caused increased matriptase zymogen activation, likely as an indirect result of increased prostasin proteolysis. This increase in activated matriptase, however, only had a negligible role in depletion of HAI-1 monomer. Our study suggests that the constitutive, high level of prostasin zymogen activation and the cell-type selective functional relationship between HAI-2 and prostasin renders Caco-2 cells more susceptible than HaCaT cells to the loss of HAI-2, causing a severe imbalance favoring prostasin proteolysis.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34089062      PMCID: PMC8444455          DOI: 10.1093/hmg/ddab150

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   5.121


  54 in total

1.  Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor.

Authors:  T Kawaguchi; L Qin; T Shimomura; J Kondo; K Matsumoto; K Denda; N Kitamura
Journal:  J Biol Chem       Date:  1997-10-31       Impact factor: 5.157

2.  Matriptase and prostasin proteolytic activities are differentially regulated in normal and wounded skin.

Authors:  Shun-Cheng Chang; Chien-Ping Chiang; Chih-Hsin Lai; Po-Wen A Du; Yu-Sin Hung; Yu-Hsuan Chen; Hui-Yu Yang; Hao-Yu Fang; Shiao-Pieng Lee; Hung-Jen Tang; Jehng-Kang Wang; Michael D Johnson; Chen-Yong Lin
Journal:  Hum Cell       Date:  2020-07-02       Impact factor: 4.174

3.  Conserved expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin in human colorectal carcinomas.

Authors:  H Kataoka; H Itoh; H Uchino; R Hamasuna; N Kitamura; K Nabeshima; M Koono
Journal:  Cancer Lett       Date:  2000-02-01       Impact factor: 8.679

4.  Regulation of the matriptase-prostasin cell surface proteolytic cascade by hepatocyte growth factor activator inhibitor-1 during epidermal differentiation.

Authors:  Ya-Wen Chen; Jehng-Kang Wang; Feng-Pai Chou; Chiu-Yuan Chen; Ellen A Rorke; Li-Mei Chen; Karl X Chai; Richard L Eckert; Michael D Johnson; Chen-Yong Lin
Journal:  J Biol Chem       Date:  2010-08-09       Impact factor: 5.157

5.  DNA targeting specificity of RNA-guided Cas9 nucleases.

Authors:  Patrick D Hsu; David A Scott; Joshua A Weinstein; F Ann Ran; Silvana Konermann; Vineeta Agarwala; Yinqing Li; Eli J Fine; Xuebing Wu; Ophir Shalem; Thomas J Cradick; Luciano A Marraffini; Gang Bao; Feng Zhang
Journal:  Nat Biotechnol       Date:  2013-07-21       Impact factor: 54.908

6.  Inactivation of serine protease Matriptase1a by its inhibitor Hai1 is required for epithelial integrity of the zebrafish epidermis.

Authors:  Thomas J Carney; Sophia von der Hardt; Carmen Sonntag; Adam Amsterdam; Jacek Topczewski; Nancy Hopkins; Matthias Hammerschmidt
Journal:  Development       Date:  2007-08-29       Impact factor: 6.868

7.  Matriptase drives early-onset intestinal failure in a mouse model of congenital tufting enteropathy.

Authors:  Roman Szabo; LuLu K Callies; Thomas H Bugge
Journal:  Development       Date:  2019-11-18       Impact factor: 6.862

8.  Matriptase autoactivation is tightly regulated by the cellular chemical environments.

Authors:  Jehng-Kang Wang; I-Jou Teng; Ting-Jen Lo; Sean Moore; Yee Hui Yeo; Yun-Chung Teng; Malvika Kaul; Chiann-Chyi Chen; Annie Hong Zuo; Fen-Pai Chou; Xiaoyu Yang; I-Chu Tseng; Michael D Johnson; Chen-Yong Lin
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

9.  Natural Endogenous Human Matriptase and Prostasin Undergo Zymogen Activation via Independent Mechanisms in an Uncoupled Manner.

Authors:  Hui Chen Su; Yan A Liang; Ying-Jung J Lai; Yi-Lin Chiu; Robert B Barndt; Frank Shiao; Hsiang-Hua D Chang; Dajun D Lu; Nanxi Huang; Chun-Che Tseng; Jehng-Kang Wang; Ming-Shyue Lee; Michael D Johnson; Shih-Ming Huang; Chen-Yong Lin
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

10.  Loss of HAI-2 in mice with decreased prostasin activity leads to an early-onset intestinal failure resembling congenital tufting enteropathy.

Authors:  Roman Szabo; Thomas H Bugge
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

View more
  1 in total

Review 1.  Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease.

Authors:  Thomas Bais; Ron T Gansevoort; Esther Meijer
Journal:  Drugs       Date:  2022-07-19       Impact factor: 11.431

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.